Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT T417_D419delinsI||Advanced Solid Tumor||conflicting||Imatinib||Preclinical - Cell culture||Actionable||In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation in transformed cells over expressing KIT T417_D419delinsI in culture (PMID: 16015387).||16015387|
|KIT T417_D419delinsI||Advanced Solid Tumor||conflicting||Imatinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing KIT T417_D419delinsI were resistant to treatment with Gleevec (imatinib) in culture (PMID: 24205792).||24205792|
|PubMed Id||Reference Title||Details|
|(24205792)||Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.||Full reference...|
|(16015387)||Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.||Full reference...|